文章：

儿科肿瘤中肠道与肿瘤微生物群的平行变化：对疾病进展与治疗反应的潜在影响

Parallel Alterations in Gut and Tumor Microbiota in Pediatric Oncology: Potential Impacts on Disease Progression and Treatment Response

原文发布日期：25 October 2025

DOI: 10.3390/cancers17213426

类型: Article

开放获取: 是

英文摘要：

In the last decade, knowledge of gut microbiota has expanded. Several studies have demonstrated a correlation between certain diseases and alterations in gut microbiota. A comprehensive understanding of this complex ecosystem is still lacking; however, this review highlights the importance of microorganisms in oncology. Recently, several studies have demonstrated that the gut microbiota influences therapeutic efficacy and tumor formation, also known as tumorigenesis. We must remember that these microorganisms also play a crucial role in tumor prognosis. Since the discovery ofFusobacterium nucleatumin colorectal carcinoma (CRC), it has been established that tumor tissues are not sterile and contain microorganisms that can lead to either beneficial or harmful pathways, affecting tumor size and response to chemotherapeutic agents. Additionally, it should be noted that data on the pediatric population are limited, as this area has not been widely researched due to the low number of cases and the complexity of therapeutic approaches. In children, the only available data are mainly based on hematological malignancies, such as acute lymphoblastic leukemia (ALL). For a better understanding, larger cohorts are required.

摘要翻译： 

过去十年间，人们对肠道微生物群的认知不断深化。多项研究证实特定疾病与肠道菌群改变存在相关性。尽管目前对这一复杂生态系统的全面认识仍有不足，但本综述着重阐述了微生物在肿瘤学领域的重要性。近期研究表明，肠道微生物群不仅影响肿瘤形成（即肿瘤发生过程），还调控治疗反应。必须认识到这些微生物在肿瘤预后中也发挥着关键作用。自具核梭杆菌在结直肠癌中被发现以来，研究已证实肿瘤组织并非无菌环境，其内定植的微生物可通过不同途径影响肿瘤体积及化疗药物反应，产生或有益或有害的生物学效应。需要特别指出的是，目前关于儿童群体的研究数据较为有限，这主要源于病例数量稀少及治疗方案的复杂性导致的科研瓶颈。现有儿童数据主要集中于急性淋巴细胞白血病等血液系统恶性肿瘤领域。为深化理解，亟需开展更大规模的队列研究。

原文链接：

Parallel Alterations in Gut and Tumor Microbiota in Pediatric Oncology: Potential Impacts on Disease Progression and Treatment Response